Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL)

被引:13
作者
Liu, Bin [1 ]
Li, Bo [2 ]
Zhou, Pingting [3 ]
Yue, Wenqin [1 ]
Wang, Tao [1 ]
Wang, Jianmin [1 ]
Hu, Xiaoxia [1 ]
Zhang, Weiping [1 ]
Chen, Jie [1 ]
Chen, Li [1 ]
Gao, Lei [1 ]
He, Miaoxia [4 ]
Yang, Jianmin [1 ]
机构
[1] Second Mil Med Univ, Changhai Hosp, Dept Hematol, Shanghai 200933, Peoples R China
[2] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Dept Radiat Oncol, Shanghai Peoples Hosp 9, Shanghai, Peoples R China
[4] Second Mil Med Univ, Changhai Hosp, Dept Pathol, Shanghai 200433, Peoples R China
关键词
D-dimer; Prognostic marker; Diffuse large B cell lymphoma (DLBCL); Survival; COLORECTAL-CANCER; PROSTATE-CANCER; LUNG-CANCER; SOLUBLE INTERLEUKIN-2-RECEPTOR; FIBRINOLYTIC PROFILES; ACTIVATION MARKERS; PLUS RITUXIMAB; BREAST-CANCER; TUMOR STAGE; COAGULATION;
D O I
10.1016/j.cca.2018.04.013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background. We assessed the prognostic significance of D-dimer in patients of diffuse large B cell lymphoma (DLBCL). Methods: We performed a retrospective study including 254 patients who were newly diagnosed DLBCL. X-tile was used to generate a cutoff value for D-dimer. Both univariate screen by Cox proportional hazard model and multivariable analysis by Cox regression model were used to assess the impact of pretreatment D-dimer levels on the overall survival (OS). Result: According to X-tile, the optimal cut-off value of D-dimer for prediction of survival was set as 1.6 mu g/mL, and a D-dimer level >= 1.6 mu g/mL was significantly associated with poor overall survival (OS) (OS: 31.7 vs. 79.1%, P < 0.001). In multivariable analysis, it was found that a higher D-dimer level was an independent predictor for worse OS (Hazard ratio (HR): 3.594 95% Confidence interval (CI): 2.296-5.267, P < 0.001). In subgroup analysis of International Prognostic Index (IPI), survival of low-risk and intermediate-risk group with a D-dimer level >= 1.6 mu g/mL were both similar to that of the high-risk group (OS: 31.6 vs. 36.5%, P = 0.957; OS: 38.0 vs. 36.5%, P = 0.758). In addition, among patients treated with surgery, those with higher D-dimer had substantially worse survival than that with lower D-dimer (OS: 27.0 vs. 84.5%, P < 0.001). Conclusion: Pretreatment D-dimer is a simple but effective predictor of survival among patients with DLBCL.
引用
收藏
页码:191 / 198
页数:8
相关论文
共 48 条
[31]   CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group [J].
Pfreundschuh, Michael ;
Trumper, Lorenz ;
Osterborg, Anders ;
Pettengell, Ruth ;
Trneny, Marek ;
Imrie, Kevin ;
Ma, David ;
Gill, Devinder ;
Walewski, Jan ;
Zinzani, Pier-Luigi ;
Stahel, Rolf ;
Kvaloy, Stein ;
Shpilberg, Ofer ;
Jaeger, Ulrich ;
Hansen, Mads ;
Lehtinen, Tuula ;
Lopez-Guillermo, Armando ;
Corrado, Claudia ;
Scheliga, Adriana ;
Milpied, Noel ;
Mendila, Myriam ;
Rashford, Michelle ;
Kuhnt, Evelyn ;
Loeffler, Markus .
LANCET ONCOLOGY, 2006, 7 (05) :379-391
[32]  
Roselli M, 2003, THROMB HAEMOSTASIS, V89, P177
[33]  
Rowbotham B J, 1990, Blood Coagul Fibrinolysis, V1, P653
[34]  
ROWBOTHAM BJ, 1987, THROMB HAEMOSTASIS, V57, P59
[35]   Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia [J].
Sehn, LH ;
Donaldson, J ;
Chhanabhai, M ;
Fitzgerald, C ;
Gill, K ;
Klasa, R ;
MacPherson, N ;
O'Reilly, S ;
Spinelli, JJ ;
Sutherland, J ;
Wilson, KS ;
Gascoyne, RD ;
Connors, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5027-5033
[36]   ACTIVATION OF COAGULATION AND FIBRINOLYSIS IN PATIENTS WITH LUNG-CANCER - RELATION TO TUMOR STAGE AND PROGNOSIS [J].
SEITZ, R ;
RAPPE, N ;
KRAUS, M ;
IMMEL, A ;
WOLF, M ;
MAASBERG, M ;
EGBRING, R ;
PFAB, R ;
HAVEMANN, K .
BLOOD COAGULATION & FIBRINOLYSIS, 1993, 4 (02) :249-254
[37]   A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
SHIPP, MA ;
HARRINGTON, DP ;
ANDERSON, JR ;
ARMITAGE, JO ;
BONADONNA, G ;
BRITTINGER, G ;
CABANILLAS, F ;
CANELLOS, GP ;
COIFFIER, B ;
CONNORS, JM ;
COWAN, RA ;
CROWTHER, D ;
DAHLBERG, S ;
ENGELHARD, M ;
FISHER, RI ;
GISSELBRECHT, C ;
HORNING, SJ ;
LEPAGE, E ;
LISTER, TA ;
MEERWALDT, JH ;
MONTSERRAT, E ;
NISSEN, NI ;
OKEN, MM ;
PETERSON, BA ;
TONDINI, C ;
VELASQUEZ, WA ;
YEAP, BY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994
[38]   Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone [J].
Suzuki, Kazuhito ;
Terui, Yasuhito ;
Yokoyama, Masahiro ;
Ueda, Kyoko ;
Nishimura, Noriko ;
Mishima, Yuko ;
Sakajiri, Sakura ;
Tsuyama, Naoko ;
Takeuchi, Kengo ;
Hatake, Kiyohiko .
LEUKEMIA & LYMPHOMA, 2013, 54 (11) :2412-2417
[39]   The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J].
Swerdlow, Steven H. ;
Campo, Elias ;
Pileri, Stefano A. ;
Harris, Nancy Lee ;
Stein, Harald ;
Siebert, Reiner ;
Advani, Ranjana ;
Ghielmini, Michele ;
Salles, Gilles A. ;
Zelenetz, Andrew D. ;
Jaffe, Elaine S. .
BLOOD, 2016, 127 (20) :2375-2390
[40]   SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma [J].
Tomita, Naoto ;
Sakai, Rika ;
Fujisawa, Shin ;
Fujimaki, Katsumichi ;
Taguchi, Jun ;
Hashimoto, Chizuko ;
Ogawa, Koji ;
Yamazaki, Etsuko ;
Ishigatsubo, Yoshiaki .
CANCER SCIENCE, 2012, 103 (08) :1518-1523